Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Not yet recruiting 3Recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE 1Esophageal Squamous Cell Carcinoma 1Breast Neoplasms 1

Interventions

Carboplatin 79Cisplatin 74Bevacizumab 62Radiotherapy 59Drug Therapy 57Capecitabine 57Oxaliplatin 56tislelizumab 54toripalimab 45Paclitaxel 44Gemcitabine 43Specimen Handling 41pembrolizumab 40anlotinib 40sintilimab 37Cyclophosphamide 34130-nm albumin-bound paclitaxel 34Injections 29Pemetrexed 28camrelizumab 26Surgical Procedures, Operative 26Magnetic Resonance Spectroscopy 26lenvatinib 24apatinib 23Docetaxel 23Etoposide 22Biopsy 22S 1 (combination) 21Fluorouracil 21Immune Checkpoint Inhibitors 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × ivarmacitinib × Clear all
NCT07505186 2026-04-01

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Not yet recruiting
45 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07313202 2025-12-31

Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance

Fujian Cancer Hospital

Phase 2 Not yet recruiting
72 enrolled
Other solid neoplasm

Patients With Advanced Solid Tumors Who Discontinued Treatment Due to irAE

NCT06731153 2024-12-12

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Fudan University

Phase 2 Not yet recruiting
40 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡